Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.

Slides:



Advertisements
Similar presentations
Atopic & Contact Dermatitis
Advertisements

Eucrisa™ - Crisaborole
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Understanding Treatment Goals for Patients With Onychomycosis
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape  Mark Boguniewicz, MD, Luz Fonacier, MD, Emma Guttman-Yassky,
Clinical Trials in IBD.
Improving Survival in Glioblastoma Multiforme
Essential Updates in Atopic Dermatitis:
Advanced NSCLC Without Actionable Mutations
Goals of Therapy for Patients With UC
Thrombosis, Cancer, and NOACs
At The Cutting Edge of Developments in the Management of Hyperkalemia
Improving Acne Outcomes
Atopic Dermatitis Treatment Landscape
Updates in Management of Atopic Dermatitis From Real Patient Cases
Atopic Dermatitis Treatment Landscape
Program Goals. Program Goals What is Atopic Dermatitis?
PARP Inhibitors and Cancer: What Do You Need to Know?
Getting the Best out of Guidelines in the Rapidly Changing Landscape of RA Treatment.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Chronic Idiopathic Urticaria
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Tailoring Hemophilia Prophylaxis Therapy
Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice
Translating Atopic Dermatitis
Next-Gen Psoriasis Therapies:
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
Emerging Atopic Dermatitis Treatments:
Tackling Atopic Dermatitis
Ask the Experts.
Mutational Testing to Select Novel Targeted Therapies in AML
Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.
The New Landscape of ABSSTI Treatment Opportunities to Improve Patient Care.
Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.
Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.
Advancing the Treatment of IBD With Biologics
The Evolving Treatment Landscape in Atopic Dermatitis
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Oral Prostanoids and PAH
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
When to Start and What to Use
What's New in Therapeutic Options for Moderate to Severe RA?
Factor Xa Inhibitors in PAD
Understanding and Addressing the Needs of Patients With AD
Guide to Atopic Dermatitis
Cancer-Associated Thrombosis
Atopic Dermatitis in the Pediatric Practice
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
EGPA.
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Are We Making Progress in the Management of Huntington Disease?
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.
Oral Prostacyclin Pathway Agents in PAH
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
Update on the Management of Atopic Dermatitis
Incorporating Prostacyclins Into Practice
From Adjuvant to Metastatic in Melanoma
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Renal Function and Myeloma Therapeutics
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Checkpoint Inhibitors in First-Line Advanced NSCLC
Tailoring Therapy in the Newly Diagnosed Patient With CLL
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Behçet Syndrome (BS) Overview
Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.
Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.
Immune Checkpoint Inhibitors in Lung Cancer
Comprehensive Acne Management
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults  Eric L. Simpson, MD, MCR,
Presentation transcript:

Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis

Diagnosing AD

All That Itches Is Not AD

Eczema (AD) Action Plans

Topical Corticosteroids First-line AD Treatment

TCIs In the Guidelines, but Still Off-labela

Topical Antihistamines in AD

Oral Antihistamines A Potential Weapon Against Pruritus

What to Consider When Patients Do Not Respond

Maintenance Therapy With Dilute Bleach Baths

Use of Systemic Agents Varies Widely for Moderate-to-Severe AD

Patient and Caregiver Education Is Vital to Treatment Success

Alternative Treatments for AD Are No Longer on the Fringe

Crisaborole 2% Ointment Emerging Topical Therapy for Mild-to-Moderate AD

PDE4 Inhibitors and Other Emerging Agents Phase 2+ Trials

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)